🧪 MATTERHORN Trial (NEJM July 2025): Perioperative Durvalumab + FLOT in Gastric & GEJ Cancer 📊 Design: Phase 3, randomized, double-blind trial (n=948) comparing durvalumab + FLOT vs placebo + FLOT in resectable stage II–IVA gastric/GEJ adenocarcinoma. ✅ Primary Endpoint:

🤖 AI-Powered Prediction of Neoadjuvant Therapy Response in Breast Cancer 📊 Study Summary: Researchers developed an AI-driven Integrated Predictive Model (IPM) combining clinical, histopathological, and immune data to predict response to neoadjuvant therapy (NAT) in breast

🧬 Phase I Trial: Cisplatin + Berzosertib + Veliparib for DDR Disruption 📌 Objective: To potentiate cisplatin’s effect by inducing a BRCA-null–like DNA damage response (DDR) phenotype using berzosertib (ATR inhibitor) and veliparib (PARP inhibitor). 👥 Design & Regimen:

🧬 Real-World Patterns of gBRCA Testing & PARPi Use in HER2– Metastatic Breast Cancer (mBC) 📌 Purpose: To evaluate real-world trends in germline BRCA (gBRCA) testing and PARP inhibitor (PARPi) use in HER2-negative mBC from 2014–2022. 👥 Cohort: •15,006 HER2– mBC patients (US

🧪 Study Summary: Divergent Lesion Behavior in aHCC Challenges Use of PFS as a Surrogate Endpoint 📌 Purpose: To investigate how individual liver lesions behave over time in patients with advanced hepatocellular carcinoma (aHCC) receiving systemic therapy, and assess

📌 Study Summary: Serial Serum Mesothelin as a Biomarker in Pleural Mesothelioma (PM) 🧪 Purpose: To evaluate whether serial serum mesothelin (SM) levels can reliably track disease status in pleural mesothelioma, potentially offering a convenient adjunct to CT scans. 🧬

DREAMM-7 Phase 3 Trial: BVd vs DVd in Relapsed/Refractory Multiple Myeloma 📌 Objective: Compare belantamab mafodotin + bortezomib + dexamethasone (BVd) vs daratumumab + bortezomib + dexamethasone (DVd) in RRMM patients after ≥1 prior line. 👥 Population: 494 patients

🧠 Fatigue in Long-Term Cancer Survivors: A Predictor of Mortality 🔍 Study Overview: CAESAR study assessed fatigue in 6057 breast, prostate, or colorectal cancer survivors (5–16 years post-diagnosis) vs cancer-free controls, and explored its link to mortality. ⸻ ✅ Key

🫀 Cardiotoxicity in Breast Cancer Survivors: A Growing Concern in the HER2 Era 🔍 Overview: •Adjuvant radiation therapy (RT) improves locoregional control and disease-free survival in breast cancer. •However, incidental cardiac exposure from RT and HER2-targeted therapies

🧪 Bulumtatug Fuvedotin (BFv): A Promising Nectin-4 Targeted ADC in Solid Tumors 🔍 Study Highlights: •First-in-human, multi-phase trial of bulumtatug fuvedotin (BFv), a Nectin-4–targeting ADC delivering MMAE, in patients with advanced solid tumors (N=274). •Included patients

EGFR-mutant NSCLC: Evolving Landscape 🧬💊 Targeted EGFR TKIs have transformed NSCLC care, now used from early to metastatic stages. 🫁 While combinations improve PFS, they raise toxicity and cost—making biomarker-driven patient selection essential. New insights into

SANO Trial Summary: Active Surveillance vs Surgery in Esophageal Cancer 🥼🫁 📌 Context: Patients with locally advanced esophageal cancer achieving clinical complete response (cCR) after neoadjuvant chemoradiotherapy (nCRT) may safely opt for active surveillance instead of

ASCO updates stage IV NSCLC without driver mutation guidelines #LCSM doi.org/10.1200/JCO-25…

ASCO updates stage IV NSCLC with driver mutation guideline #lcsm ascopubs.org/doi/full/10.12…

Myelofibrosis - recommendations for Asia Pacific from APAC-MF Alliance doi.org/10.1200/OP-24-…

Radio- chemotherapy induced oral mucositis - prevention and management doi.org/10.1038/s41368…

Even though I've used SG only once and I've never used DatoDxD - as an academic exercise I wanted to review the ADR profile of both ADCs. Made a small infographic card for the same. Hope it is useful for ppl who need it. Oncology Brothers Dr Amol Akhade Paolo Tarantino Yakup Ergün

VIKTORIA-1 trial: Gedatolisib (dual PI3K/mTOR inhibitor) + fulvestrant ± palbo in HR+/HER2–, PIK3CA WT ABC, post-CDK4/6i. Prees relase . 📊 Triplet mPFS: 9.3 mo ⚪ Fulvestrant: 2.0 mo 🟢 Delta: +7.3 mo | HR: 0.24 But is that delta real? 🤔 📉 Fulvestrant-only arms in other